DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 21526/S-029

SUPPLEMENT APPROVAL

Gilead Sciences, Inc.
Attention: Shalini Gidwani, MSc, RAC
Director, Regulatory Affairs
333 Lakeside Drive
Foster City, CA 94404

Dear Ms. Gidwani:

Please refer to your Supplemental New Drug Application (sNDA) dated April 29, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ranexa, (ranolazine) 500 and 1000 mg extended-release Tablets.

This Prior Approval supplemental new drug application proposes a deletion from section 6.1 and addition to section 6.2. In addition revisions from approved supplement 028 were incorporated into this supplement. Content changes were made as follows:

1. Under **ADVERSE REACTIONS**, section 6.1 **Clinical Trial Experiences**, subsection ***Laboratory Abnormalities***, the following sentence was removed:

   RANEXA produces small reductions in hemoglobin A1c. RANEXA is not a treatment for diabetes.

2. Under **ADVERSE REACTIONS**, section 6.2 **Post Marketing Experience**, the following section was added:

   Metabolism and Nutrition Disorders
   Cases of hypoglycemia have been reported in diabetic patients on antidiabetic medication.

3. Incorporation of changes from S-028 to include conformance to PLLR.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Alexis Childers, Sr. Regulatory Project Manager, at (301) 796-0442.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
01/06/2016